<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>multi-selective inhibitors &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/multi-selective-inhibitors/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 14 Mar 2025 18:31:03 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>multi-selective inhibitors &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Immunotherapy Enhances Effectiveness of KRAS-Targeted Treatments in Pancreatic Cancer</title>
		<link>https://bioengineer.org/immunotherapy-enhances-effectiveness-of-kras-targeted-treatments-in-pancreatic-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 14 Mar 2025 18:31:03 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[immunotherapy combination]]></category>
		<category><![CDATA[KRAS-targeted therapies]]></category>
		<category><![CDATA[multi-selective inhibitors]]></category>
		<category><![CDATA[Pancreatic cancer treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/immunotherapy-enhances-effectiveness-of-kras-targeted-treatments-in-pancreatic-cancer/</guid>

					<description><![CDATA[In a groundbreaking study that has the potential to reshape the treatment landscape for pancreatic cancer, researchers from the Perelman School of Medicine at the University of Pennsylvania have demonstrated that the addition of immunotherapy to a novel class of multi-selective inhibitors targeting the notorious cancer-causing gene mutation, KRAS, can significantly improve treatment outcomes in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">238452</post-id>	</item>
	</channel>
</rss>
